Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.

Jinlu Yang

Yan Zhang

Chuanwu Zhao

Xuejiao Zhang

Qian Guo

Shuxiang Cui

Chunhua Jiang

Jieqiong Kang

Peipei Zhao

Provided in the present invention are a compound as represented by formula (I), or a pharmaceutically acceptable salt, a tautomer, a geometrical isomer, an optical isomer, a solvate or an isotopic derivative thereof, and the use thereof. The compound of the present invention has a significant inhibitory activity on PRMT5, has a significant inhibitory effect on tumor cells and in vivo tumor models, also has a good administration performance, and has clinical application potential for preventing and/or treating diseases which are at least partially mediated by PRMT5.

3,4-dihydroisoquinoline compound and use thereof

A compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof can be used in preparing a pharmaceutical composition. The compound or the pharmaceutical composition can be used in the preparation a drug for the prevention and/or treatment of cancer, tumors, viral infections, depression, neurological disorders, trauma, age-related cataracts, organ transplant rejection or autoimmune diseases.

Targeted ubiquitination degradation BRD4 protein compound, preparation method therefor and application thereof

Growing community of inventors

Shijiazhuang, China

Jinlu Yang